Approval after phase I: ceritinib runs the three-minute mile.
about
Second- and third-generation ALK inhibitors for non-small cell lung cancerNCI-60 Cell Line Screening: A Radical Departure in its Time.International Clinical Trials Day 2014-ancient and modern needs.Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with CrizotinibSufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"Breakthrough Drugs and Turtle Soup.Defining a new role for the National Cancer Institute cooperative groups: more science, fewer trials.What is the future for cancer clinical trials?Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.
P2860
Q28072496-DE4816A5-ABAB-4FCB-9B22-D9285103912CQ30383428-7FB15AAC-D27B-42E5-B90A-89D69E18E825Q33649540-4E212B3E-B0C7-4253-8B42-91F5C5B8F0E0Q35168766-7CDD205E-F792-4381-A6A4-7F2E76C44520Q38567805-867942F7-39F2-461E-BD14-F0467C68AB69Q38721743-792E42D1-DC31-4517-BE0F-19063B7CAD6EQ39079095-CBBBEC90-7D7C-41E0-9794-A32C97B55FBDQ40996798-026F8C59-E4A9-4F9E-9A94-86B5ED120163Q42333176-EA1D776B-3C35-4407-8C2D-E58C022CBF70Q42415372-BDE4BEDB-A951-46A5-B1F2-181BCC1CB656Q42976625-DD5FD57A-8F55-4666-8A41-6562C9AD0E9EQ48639219-4683CAD0-5C1E-43A1-98C0-6C04D42733DBQ52673089-42C82009-1925-45A2-BF8B-E069EDEA56F2
P2860
Approval after phase I: ceritinib runs the three-minute mile.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Approval after phase I: ceritinib runs the three-minute mile.
@en
Approval after phase I: ceritinib runs the three-minute mile.
@nl
type
label
Approval after phase I: ceritinib runs the three-minute mile.
@en
Approval after phase I: ceritinib runs the three-minute mile.
@nl
prefLabel
Approval after phase I: ceritinib runs the three-minute mile.
@en
Approval after phase I: ceritinib runs the three-minute mile.
@nl
P2860
P1433
P1476
Approval after phase I: ceritinib runs the three-minute mile.
@en
P2093
Bruce A Chabner
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0143
P577
2014-05-01T00:00:00Z